Search

Meloxicam is a nonsteroidal anti-inflammatory drug commonly used in avian species. In this study, the pharmacokinetic parameters for meloxicam were determined following single intravenous (i.v.), intramuscular (i.m.) and oral (p.o.) administrations of the drug (1 mg/kg·b.w.) in adult African grey parrots ( Psittacus erithacus; n = 6). Serial plasma samples were collected and meloxicam concentrations were determined using a validated high-performance liquid chromatography assay. A noncompartmental pharmacokinetic analysis was performed. No undesirable side effects were observed during the study. After i.v. administration, the volume of distribution, clearance and elimination half-life were 90.6 ± 4.1 mL/kg, 2.18 ± 0.25 mL/h/kg and 31.4 ± 4.6 h, respectively. The peak mean ± SD plasma concentration was 8.32 ± 0.95 μg/ mL at 30 min after i.m. administration. Oral administration resulted in a slower absorption ( tmax = 13.2 ± 3.5 h; Cmax = 4.69 ± 0.75 μg/ mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route. At 24 h, concentrations were 5.90 ± 0.28 μg/ mL for i.v., 4.59 ± 0.36 μg/ mL for i.m. and 3.21 ± 0.34 μg/ mL for p.o. administrations and were higher than those published for Hispaniolan Amazon parrots at 12 h with predicted analgesic effects. [ABSTRACT FROM AUTHOR]

OBJECTIVE To determine the pharmacokinetics of meloxicam in African grey parrots (Psittacus erithacus) during administration of multiple doses. ANIMALS 6 healthy African grey parrots. PROCEDURES Meloxicam was administered at each of 3 dosages (1 mg/kg, IM, q 24 h, for 7 days; 1 mg/kg, PO, q 24 h, for 12 days; and 1.6 mg/kg, PO, q 24 h, for 7 days) with an 8-week washout period between treatments. Blood samples were collected 12 and 24 hours after each drug administration (times of presumptive peak and trough drug concentrations) for pharmacokinetic analysis. Birds were visually assessed during all experiments and monitored for changes in selected plasma and urine biochemical variables after administration of the drug at 1.6 mg/kg. RESULTS Mean trough plasma concentrations at steady state were 10.7 and 9.16 μg/mL after meloxicam administration at 1 mg/kg, IM, and 1 mg/kg, PO, respectively. Plasma drug accumulation was evident (accumulation ratios of 2.04 ± 0.30 [IM treatment] and 2.45 ± 0.26 [PO treatment]). Plasma and urine N-acetyl-β-d-glucosaminidase activities were significantly increased at the end of meloxicam treatment at 1.6 mg/kg. CONCLUSIONS AND CLINICAL RELEVANCE Plasma concentrations of meloxicam were maintained at values greater than effective analgesic concentrations described for other avian species. Although administration of meloxicam at a dosage of 1 mg/kg IM and PO daily for 1 week and 12 days, respectively, was not associated with adverse clinical effects in this population, further studies are needed to assess the efficacy and safety of the drug during prolonged treatment and the clinical relevance of its accumulation.

This article outlines a practical approach for the use of blood-gas analysis in pet rabbits using the I-STAT analyzer. Sampling techniques and a theoretic approach to diagnosis are described. The following 95% RI were obtained from venous samples of 45 healthy rabbits: pH (7.245-7.533), PCO(2) (28.9-52.9 mm Hg), HCO(3) (17.0-32.5 mmol/L), total CO(2) (18-34 mmol/L), BE(ecf) (-10-8 mmol/L), AnGap (11-26 mmol/L), Na (136-147 mmol/L), K (3.4-5.7 mmol/L), Cl (93-113 mmol/L), Glu (93-245 mg/dL), BUN (9-33 mg/dL). Results from 20 arterial samples were pH (7.358-7.502), PCO(2) (29.1-36.8 mm Hg), HCO(3) (17.5-27.6 mmol/L), BE(ecf) (-7-5 mmol/L), PO(2) (75-101 mm Hg), iCa (1.67-1.85). The article also includes some conclusions obtained comparing results from healthy and ill rabbits over an 18-month period., (Copyright © 2013 Elsevier Inc. All rights reserved.)